{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:14:46Z","timestamp":1793650486741,"version":"4.5.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In the phase III POETYK PSO-1 and PSO-2 trials, deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, was well tolerated and efficacious over 1\u2005year in patients with psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate deucravacitinib safety and efficacy over 2\u2005years in patients participating in the phase III trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In the POETYK long-term extension (LTE), an ongoing phase IIIb open-label trial, adults with moderate-to-severe plaque psoriasis who completed PSO-1 or PSO-2 receive deucravacitinib 6\u2005mg once daily. Safety was assessed via adverse events (AEs) and laboratory parameter abnormalities. Efficacy endpoints, including \u2265 75% reduction from baseline Psoriasis Area and Severity Index score (PASI 75) and static Physician\u2019s Global Assessment (sPGA) score of 0\/1 (clear\/almost clear), were evaluated in patients originally randomized to deucravacitinib, patients who crossed over from placebo at week 16 and patients who achieved PASI 75 at week 24 (peak efficacy).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At data cutoff (1 October 2021), 1519 patients had received at least one dose of deucravacitinib; 79.0% and 39.9% had \u2265 52 weeks and \u2265 104 weeks of total deucravacitinib exposure, respectively. Exposure-adjusted incidence rates (EAIRs) per 100 person-years were similar at 1\u2005year and 2\u2005years for any AEs (229.2 vs. 154.4, respectively), serious AEs (5.7 vs. 6.1), discontinuations (4.4 vs. 2.8), deaths (0.2 vs. 0.4), serious infections (1.7 vs. 2.6), herpes zoster (0.9 vs. 0.8), major adverse cardiovascular events (0.3 vs. 0.4), venous thromboembolic events (0.2 vs. 0.1) and malignancies (1.0 vs. 0.9). EAIRs for COVID-19 infections were higher at 2\u2005years than at 1\u2005year (5.1 vs. 0.5) owing to the peak of the global COVID-19 pandemic occurring during the LTE. No clinically meaningful changes from baseline or trends were observed over 2\u2005years in haematological, chemistry or lipid parameters. Clinical responses were maintained in patients who received continuous deu\u00adcravacitinib treatment from baseline [PASI 75: week 52, 72.4%; week 112, 79.7%; sPGA 0\/1: week 52, 57.9%; week 112, 61.1% (as observed)]. Responses at week 52 were also maintained in placebo crossovers and in week-24 PASI-75 responders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Deucravacitinib maintained efficacy and demonstrated consistent safety with no new safety signals observed through 2\u2005years.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae014","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T22:47:17Z","timestamp":1705099637000},"page":"668-679","source":"Crossref","is-referenced-by-count":71,"title":["Deucravacitinib in plaque psoriasis: 2-year safety and\u00a0efficacy results from the phase III POETYK trials"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark","family":"Lebwohl","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust , Manchester , UK"},{"name":"NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Sofen","sequence":"additional","affiliation":[{"name":"University of California Los Angeles, David Geffen School of Medicine , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Fukuoka University Hospital , Fukuoka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-5263","authenticated-orcid":false,"given":"Carle","family":"Paul","sequence":"additional","affiliation":[{"name":"Toulouse University and CHU , Toulouse , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek\u00a0C","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Wroclaw Medical University , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Spelman","sequence":"additional","affiliation":[{"name":"Veracity Clinical Research , Brisbane, QLD , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d\u2019Azur, University Hospital of Nice , Nice , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Vritzali","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Napoli","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata M","family":"Kisa","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Buck","sequence":"additional","affiliation":[{"name":"Cytel Inc , Waltham, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck , L\u00fcbeck , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center , Portland, OR , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"2024090210051484000_ljae014-B1","first-page":"16082","article-title":"Psoriasis","volume-title":"Nat Rev Dis Primers","author":"Greb","year":"2016"},{"key":"2024090210051484000_ljae014-B2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"2024090210051484000_ljae014-B3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/17512433.2017.1293519","article-title":"Apremilast for the management of moderate to severe plaque psoriasis","volume":"10","author":"Vangipuram","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024090210051484000_ljae014-B4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","article-title":"Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis","volume":"19","author":"Torres","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2024090210051484000_ljae014-B5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13555-016-0153-2","article-title":"Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data","volume":"7","author":"Armstrong","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024090210051484000_ljae014-B6","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2024090210051484000_ljae014-B7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"2024090210051484000_ljae014-B8","author":"Sotyktu [package insert]","year":"2022"},{"key":"2024090210051484000_ljae014-B9","author":"Sotyktu Japan [package insert]","year":"2022"},{"key":"2024090210051484000_ljae014-B10","author":"Sotyktu [product monograph]","year":"2022"},{"key":"2024090210051484000_ljae014-B11","author":"Sotyktu [product information].","year":"2022"},{"key":"2024090210051484000_ljae014-B12","author":"Sotyktu [summary of product characteristics]","year":"2023"},{"key":"2024090210051484000_ljae014-B13","author":"Sotyktu [package insert]","year":"2023"},{"key":"2024090210051484000_ljae014-B14","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"2024090210051484000_ljae014-B15","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024090210051484000_ljae014-B16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024090210051484000_ljae014-B17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, Program fOr Evaluation of TYK2 inhibitor psoriasis second phase 3 trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 1","key":"2024090210051484000_ljae014-B18","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/annrheumdis-2022-eular.1377","article-title":"Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials [abstract AB0890]","volume":"81","author":"Warren","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024090210051484000_ljae014-B19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"2024090210051484000_ljae014-B20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024090210051484000_ljae014-B21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2024090210051484000_ljae014-B22","author":"FDA Briefing Document"},{"key":"2024090210051484000_ljae014-B23","author":"Dean"},{"key":"2024090210051484000_ljae014-B24","first-page":"734","article-title":"Methods for imputing missing efficacy data in clinical trials of biologic psoriasis therapies: implications for interpretations of trial results","volume":"16","author":"Langley","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"2024090210051484000_ljae014-B25","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3\u2005years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024090210051484000_ljae014-B26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/09546634.2020.1782817","article-title":"Continuous treatment with guselkumab maintains clinical responses through 4\u2005years in patients with moderate-to-severe psoriasis: results from VOYAGE 1","volume":"33","author":"Griffiths","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2024090210051484000_ljae014-B27","doi-asserted-by":"crossref","first-page":"11824","DOI":"10.1038\/s41598-021-91356-3","article-title":"Risk of herpes zoster in psoriasis patients receiving systemic therapies: a nationwide population-based cohort study","volume":"11","author":"Ting","year":"2021","journal-title":"Sci Rep"},{"key":"2024090210051484000_ljae014-B28","first-page":"573","article-title":"Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies Errata","volume":"19","author":"Gottlieb","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"2024090210051484000_ljae014-B29","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"2024090210051484000_ljae014-B30","first-page":"S690","article-title":"Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: cumulative experience [abstract 1563]","volume-title":"Arthritis Rheumatol","author":"Fiorentino","year":"2014"},{"key":"2024090210051484000_ljae014-B31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","article-title":"Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest","volume":"307","author":"Reich","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"2024090210051484000_ljae014-B32","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.14068","article-title":"Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States","volume":"173","author":"Kimball","year":"2015","journal-title":"Br J Dermatol"},{"key":"2024090210051484000_ljae014-B33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMc2009567","article-title":"Covid-19 in immune-mediated inflammatory diseases - case series from New York","volume":"383","author":"Haberman","year":"2020","journal-title":"N Engl J Med"},{"key":"2024090210051484000_ljae014-B34","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.jaad.2020.09.005","article-title":"COVID, biologics, and psoriasis therapy","volume":"83","author":"Elston","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024090210051484000_ljae014-B35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071390","article-title":"Biologics for psoriasis during the COVID-19 pandemic","volume":"10","author":"Kamiya","year":"2021","journal-title":"J Clin Med"},{"key":"2024090210051484000_ljae014-B36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ad.2020.12.001","article-title":"[Obesity\u2014a risk factor for psoriasis and COVID-19]","volume":"112","author":"Llamas-Velasco","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"2024090210051484000_ljae014-B37","doi-asserted-by":"crossref","first-page":"940756","DOI":"10.3389\/fimmu.2022.940756","article-title":"Roles and functions of SARS-CoV-2 proteins in host immune evasion","volume":"13","author":"Rashid","year":"2022","journal-title":"Front Immunol"},{"key":"2024090210051484000_ljae014-B38","doi-asserted-by":"crossref","first-page":"108234","DOI":"10.1016\/j.celrep.2020.108234","article-title":"Evasion of type I interferon by SARS-CoV-2","volume":"33","author":"Xia","year":"2020","journal-title":"Cell Rep"},{"key":"2024090210051484000_ljae014-B39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102211","article-title":"Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment","volume":"18","author":"Hu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2024090210051484000_ljae014-B40","first-page":"1002","article-title":"Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis","volume":"16","author":"Bissonnette","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"2024090210051484000_ljae014-B41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.gde.2010.11.001","article-title":"Environment, inflammation, and cancer","volume":"21","author":"Sansone","year":"2011","journal-title":"Curr Opin Genet Dev"},{"key":"2024090210051484000_ljae014-B42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2024090210051484000_ljae014-B43","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2024090210051484000_ljae014-B44","doi-asserted-by":"crossref","first-page":"687432","DOI":"10.3389\/fonc.2021.687432","article-title":"Incidence of skin cancer in patients with chronic inflammatory cutaneous diseases on targeted therapies: a systematic review and meta-analysis of observational studies","volume":"11","author":"Crisafulli","year":"2021","journal-title":"Front Oncol"},{"key":"2024090210051484000_ljae014-B45","first-page":"1441","article-title":"Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies","volume":"13","author":"Gottlieb","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"2024090210051484000_ljae014-B46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae014\/56879509\/ljae014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/5\/668\/58993250\/ljae014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/5\/668\/58993250\/ljae014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T12:42:36Z","timestamp":1725280956000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/5\/668\/7558435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,1,16]]},"published-print":{"date-parts":[[2024,4,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae014","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,1,16]]}}}